Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'A Phase 2 Platform Basket Study Evaluating Advanced Therapies in Subjects with Moderately to Severe... Read More
Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'Evaluating the Year-Round Immunogenicity of Standard-Dose Versus High-Dose Seasonal Influenza Vacci... Read More
Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion,... Read More
Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-Label Study of Rinzimetostat (ORIC-944) in Combination with Darolutamid... Read More
Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'Tucatinib continuation protocol: an open label study for participants from tucatinib clinical studi... Read More
Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'A PHASE III, MULTICENTER, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY O... Read More
Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'An Interventional Phase 3, Open Label, Randomized Study To Evaluate Efficacy And Safety of PF-08634... Read More
Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Double-blind, Phase 3 Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy Wit... Read More
Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Vers... Read More
Singapore, Oct. 2 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Vers... Read More